The present invention relates to a pharmaceutical composition for the oral administration of a therapeutic compound of formula (I), which comprises granules that comprise at least therapeutic compound of formula (I) (see below), particularly 2-Methyl-2-[4-(3-methyl-2-oxo-8- quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]- propionitrile or 8-(6-methoxy-pyridin-3-yl)-3-methyl-1-(4-piperazin-1-yl-3-trifl uoromethyl-phenyl)-1,3-dihydro-imidazo[4,5-c]quinolin-2-one, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof； at least one non-ionic surfactant that is Vitamin E-TPGS in an amount ranging from about 15 to about 80% by weight of the composition； and at least one a dissolution enhancing agent selected from polyethylene glycol, polyethylene oxide, and any combination of the foregoing. The present invention also relates to processes for making such pharmaceutical compositions； a kit comprising such pharmaceutical composition and the instructions provide that the pharmaceutical composition may be taken immediately to about thirty minutes after the consumption of food； and related uses and methods of treatment.La presente invención se refiere a una composición farmacéutica para la administración oral de un compuesto terapéutico de la fórmula (I), la cual comprende gránulos que comprenden por lo menos compuesto terapéutico de la fórmula (I) (véase más adelante), en particular el 2-metil-2-[4-(3-metil-2-oxo-8-quinolin -3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionit rilo o la 8-(6-metoxi-piridin-3-il)-3-metil-1-(4-piperazin-1-il-3- trifluoro-metil-fenil)-1,3-dihidro-imidazo-[4,5-c]-quinolin-2-ona , o un tautómero de los mismos, o una sal farmacéuticamente aceptable, o un hidrato o un solvato de los mismos； por lo menos un tensoactivo no iónico que es la Vitamina E-TPGS, en una cantidad en el intervalo de aproximadamente el 15 a aproximadamente el 80 por ciento en peso de la composición； y por lo meno
